Our breadth of assays, dedicated CV expertise, and globally harmonized study execution give you the clarity needed to make timely, informed development decisions.
Identify and reduce cardiac risk before investing in more complex in vivo studies. Early assessments help you deprioritize unsafe candidates, refine structure–activity relationships, and guide downstream CV safety strategy.
Capabilities include:
Our in vivo platforms enable continuous, high‑sensitivity cardiovascular monitoring in both rodent and nonrodent species, giving you robust data to evaluate cardiac safety with confidence.
Capabilities include:
Whether you need a standalone telemetry study or CV endpoints within a toxicology package, our teams design GLP‑aligned solutions that fit your goals, reduce retesting, and maintain study continuity.
Leverage advanced microphysiological systems to gain mechanistic insight earlier. Advanced NAM platforms can reveal endothelial or thrombogenic risks that may not emerge in traditional assays—helping you make better‑informed decisions sooner.
Ensure consistency across your studies. All telemetered ECGs are reviewed by a specialized, centralized team with decades of arrhythmia expertise—improving data quality, speeding interpretation, and reducing ambiguity in safety conclusions.
Work with a team that helps you see the whole picture—not isolated data points. Our scientists integrate ion‑channel, iPSC, telemetry, and toxicology findings. This integrated approach provides a clearer risk story and strengthens your IND/CTA submissions.
Cardiometabolic therapies often require both cardiovascular and metabolic evaluation—especially within CKM‑relevant populations where metabolic status can alter cardiac risk. Cardiovascular assessment provides the foundational safety insights needed to advance CVMD programs, including:
Move your program forward without gaps or rework. Our aligned in vitro → in vivo workflow enables seamless progression from early ion‑channel profiling into GLP cardiovascular studies—reducing handoffs, simplifying planning, and accelerating readiness for regulatory review.
Generate sensitive, high‑quality cardiovascular data you can rely on. Our dedicated telemetry facilities provide controlled environments and proven platforms across rodent and large-animal models—supporting confident detection of CV effects earlier in development.
Strengthen your regulatory strategy with assessments built around current ICH E14/S7B Q&As. By integrating in vitro hERG and in vivo QT evaluations, we help reduce clinical TQT burden, support confident submissions, and provide a clear rationale for cardiac safety decisions.
